Par Committee digs hole in drug approval procedure

The Indian drug industry has received a rude shock. The Parliamentary Committee report on the central drug regulator points out serious lapses in procedure for granting drug marketing approvals, and accuses the organisation of being hand-in-glove with private parties, reports Archana Shukla of CNBC-TV18.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney
moneycontrol.com

Home » News » Business

May 11, 2012, 08.34 AM | Source: CNBC-TV18

Par Committee digs hole in drug approval procedure

The Indian drug industry has received a rude shock. The Parliamentary Committee report on the central drug regulator points out serious lapses in procedure for granting drug marketing approvals, and accuses the organisation of being hand-in-glove with private parties, reports Archana Shukla of CNBC-TV18.

Like this story, share it with millions of investors on M3

Par Committee digs hole in drug approval procedure

The Indian drug industry has received a rude shock. The Parliamentary Committee report on the central drug regulator points out serious lapses in procedure for granting drug marketing approvals, and accuses the organisation of being hand-in-glove with private parties, reports Archana Shukla of CNBC-TV18.

Post Your Comments

Share Cancel

Archana Shukla (more)

Reporter, CNBC-TV18 |

The Indian drug industry has received a rude shock. The Parliamentary Committee report on the central drug regulator points out serious lapses in procedure for granting drug marketing approvals, and accuses the organisation of being hand-in-glove with private parties, reports Archana Shukla of CNBC-TV18.

Parliamentary proceedings have thrown the Indian pharma industry for a loop. The Parliamentary Committee report on the The Central Drug Regulator contains some scathing criticism mainly regarding the manner in which drugs were granted marketing approvals.

The report, without pulling punches, accuses the drug regulator of colluding with private players when it came to approvals. The report follows an in-depth investigation of 42 randomly selected drugs from a list of 2,167 drugs approved between 2000 and 2010. It says, "Between January 2008 and October 2012, 33 drugs were approved without the mandatory clinical trials. Some of the clinical trial data submitted in the period were not performed on the mandatory trial size or patient groups. There have been cases of gross violation of the laws of the land by the CDSCO."

Only eight of 42 drugs in the list had proper follow-ups of side effects in Indian patients by doctors and manufacturers. The report also says CDSCO needs to re-examine marketing approvals for drugs like analgesic Analgin, which have been withdrawn from most other markets.

But here's the shocker: The report says it has, "adequate documentary evidence to conclude that many opinions were actually written by invisible hands drug manufacturers and experts merely obliged by putting their signatures."

So, it argues that there is a collusive nexus between drug manufacturers, some functionaries of CDSCO and some medical experts. However, some players whose name has made it into the report, refute the allegations.

Yusuf K Hamied, CMD, Cipla, said, "Two of Cipla's drugs have been named (in the report). One thing I can assure that Cipla has followed all the laws and regulations laid down in the Drugs and Cosmetics Act for grant of licences to produce products and that there has been no violations."
 
Apart from the lack of proper coordination, and a lack of physical infrastructure, the report also blames chronic staff shortage for the regulator's inefficiencies. It also says that with a mission to propagate and facilitate the drugs industry, CDSCO has failed to uphold the interests of the most important stakeholder, the Indian consumer.

Buy, Hold, Sell ? Hear it first on M3
Par Committee digs hole in drug approval procedure

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login